Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Short term Debt (2021 - 2022)

Altimmune (ALT) has disclosed Short term Debt for 6 consecutive years, with $4.3 million as the latest value for Q1 2022.

  • On a quarterly basis, Short term Debt changed N/A to $4.3 million in Q1 2022 year-over-year; TTM through Mar 2022 was $4.3 million, a N/A change, with the full-year FY2021 number at $6.1 million, changed N/A from a year prior.
  • Short term Debt was $4.3 million for Q1 2022 at Altimmune, down from $6.1 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $6.1 million in Q4 2021 to a low of $4.3 million in Q1 2022.